No offense but, what are you talking about? Is your strategy here to make a play on sales???
...a product that is this far from market
We have two phase 3 drugs. If you want to see the largest return in the shortest amount of time NOW is the time to invest. Actually, if you are confident in the product approval, just before phase 2 results is really the time to invest.
Then they are just in for a fall.
Seriously? Based on what??? That we are so overvalued currently??? I and others, said it before ASM, this should be trading between $3-$5 in phase 3. SeeThruEquity has a given a $3.40 price target. And once we uplist we will have exposure to a massive amount of new money and institutional investors.
Market Data 
Markets 
AI
